Company Overview and News
HOUSTON -- The Honghua Group Limited has awarded a $12 million front-end engineering design (FEED) contract to Wood for its LNG platform development in the West Delta area of the Gulf of Mexico.
The Honghua Group Limited has awarded Wood a $12 million front-end engineering design (FEED) contract for its liquefied natural gas (LNG) platform development in the West Delta area of the Gulf of Mexico, Wood announced Tuesday.
HOUSTON -- The Honghua Group Limited has awarded a $12-million, front-end engineering design (FEED) contract to Wood for its liquefied natural gas (LNG) platform development in the West Delta area of the Gulf of Mexico.
Honghua is banking on its new state-owned giant shareholder to bail it out of losses through clinching new orders from Chinese oil giants and financial support from Chinese banks
“Something has to change.” In a down rig market, the call-to-action weighs heavily on technology to find a way to do things differently—reduce cost, improve performance or provide another option. Innovative engineering seldom has had more fertile ground than it does today.
Honghua Group, one of the world’s largest assemblers of onshore oil and gas drilling rigs, has been folded into state-owned China Aerospace Science & Industry Corp (CASIC), in a restructuring of the unprofitable and debt-ridden rig maker amid the global slump in oil prices.
Honghua Group Ltd. has announced that Honghua Golden Coast Equipment FZE, a wholly-owned subsidiary of the Group, entered into a sales agreement with Kuwait Drilling Company K.S.C 15 March 2016. The total amount is approximately US$15 million (approximately HK$118 million). As per the agreement, a 7000 m cluster well drilling rig is expected to deliver to KDC by the end of 2016.
CHENGDU, China, March 21, 2016 /PRNewswire/ -- Honghua Group Ltd. ("HH") (Stock Code: 196.HK), a leading global land drilling rig manufacturer, is pleased to announce that Honghua Golden Coast Equipment FZE ("HH Golden Coast"), a wholly-owned subsidiary of the Group, entered into a sales agreement (the "Sales Agreement") with Kuwait Drilling Company K.S.C ("KDC") on 15 March 2016, with a total amount of approximately US$15 million (approximately HK$118 million).
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
2018-05-17 - Asif
Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...